Welcome to LookChem.com Sign In|Join Free

CAS

  • or

51-20-7

Post Buying Request

51-20-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51-20-7 Usage

Chemical Properties

Prisms from H 2 O.

Uses

A major chemical mutagen. Incorporates into DNA, altering base-pair sequencing by replacing thymine

Definition

ChEBI: A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position.

General Description

White powder.

Air & Water Reactions

Insoluble in water.

Hazard

Moderately toxic, alters DNA by replacing thymine.

Health Hazard

ACUTE/CHRONIC HAZARDS: When heated to decomposition 5-Bromouracil emits very toxic fumes of bromide ion and NOx.

Fire Hazard

Flash point data for 5-Bromouracil are not available, but 5-Bromouracil is probably combustible.

Safety Profile

Moderately toxic by intraperitoneal route. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of Brand NOx.

Check Digit Verification of cas no

The CAS Registry Mumber 51-20-7 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 1 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 51-20:
(4*5)+(3*1)+(2*2)+(1*0)=27
27 % 10 = 7
So 51-20-7 is a valid CAS Registry Number.
InChI:InChI=1/C4H3BrN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

51-20-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B0665)  5-Bromouracil  >98.0%(T)

  • 51-20-7

  • 25g

  • 590.00CNY

  • Detail
  • Alfa Aesar

  • (A14799)  5-Bromouracil, 98+%   

  • 51-20-7

  • 5g

  • 164.0CNY

  • Detail
  • Alfa Aesar

  • (A14799)  5-Bromouracil, 98+%   

  • 51-20-7

  • 25g

  • 535.0CNY

  • Detail
  • Alfa Aesar

  • (A14799)  5-Bromouracil, 98+%   

  • 51-20-7

  • 100g

  • 2003.0CNY

  • Detail
  • Aldrich

  • (852473)  5-Bromouracil  98%

  • 51-20-7

  • 852473-5G

  • 193.05CNY

  • Detail
  • Aldrich

  • (852473)  5-Bromouracil  98%

  • 51-20-7

  • 852473-25G

  • 638.82CNY

  • Detail

51-20-7Synthetic route

uracil
66-22-8

uracil

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; acetic anhydride; acetic acid at 50℃; for 1.5h; Temperature; Reagent/catalyst;99.9%
With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione; acetic anhydride; acetic acid at 50℃; for 1.5h; Temperature; Reagent/catalyst;99.9%
With N-Bromosuccinimide; montmorillonite K-10; tetrabutylammomium bromide for 0.0666667h; microwave irradiation;96%
5,5'-mercuribis(uracil)
97759-31-4

5,5'-mercuribis(uracil)

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With bromine; potassium bromide In water at 80℃; for 0.5h;84%
5-bromo-2,4-bis(4-methoxybenzyloxy)pyrimidine
664988-37-8

5-bromo-2,4-bis(4-methoxybenzyloxy)pyrimidine

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 0.25h;84%
5-bromo-2,4-dimethoxypyrimidine
56686-16-9

5-bromo-2,4-dimethoxypyrimidine

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With hydrogenchloride83%
1-Acetyl-5-trifluoroacetoxymercuriuracil

1-Acetyl-5-trifluoroacetoxymercuriuracil

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With bromine; potassium bromide In water; acetonitrile at 80℃; for 0.5h;77%
uracil
66-22-8

uracil

A

5-bromouracil
51-20-7

5-bromouracil

5,6-dibromo-5,6-dihydrouracil

5,6-dibromo-5,6-dihydrouracil

Conditions
ConditionsYield
With Bromoform In dichloromethane for 40h; Irradiation;A 7%
B 53%
sodium isoorotate
3252-17-3

sodium isoorotate

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With bromine In water for 7h; Heating;40%
3-(3,4-dihydro-5-bromo-2,4-dioxo-(2H)pyrimidin-1-yl)propanoic acid methyl ester
22384-59-4

3-(3,4-dihydro-5-bromo-2,4-dioxo-(2H)pyrimidin-1-yl)propanoic acid methyl ester

ethanolamine
141-43-5

ethanolamine

A

5-bromouracil
51-20-7

5-bromouracil

B

3-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-(2-hydroxyethyl)-propanamide
1174386-67-4

3-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-(2-hydroxyethyl)-propanamide

C

N-(2-hydroxyethyl)-3-[5-(2-hydroxyethylamino)-2,4-dioxo-3,4-dihydro(2H)pyrimidin-1-yl]propanamide
1174386-68-5

N-(2-hydroxyethyl)-3-[5-(2-hydroxyethylamino)-2,4-dioxo-3,4-dihydro(2H)pyrimidin-1-yl]propanamide

Conditions
ConditionsYield
In methanol for 12h; Reflux;A 32%
B 30%
C 35%
4-Decylsulfanyl-1H-pyrimidin-2-one

4-Decylsulfanyl-1H-pyrimidin-2-one

A

5-bromouracil
51-20-7

5-bromouracil

B

C14H23BrN2OS
856766-62-6

C14H23BrN2OS

Conditions
ConditionsYield
With bromine In tetrachloromethane at 20℃;A 30%
B 20%
4-Dodecylsulfanyl-1H-pyrimidin-2-one

4-Dodecylsulfanyl-1H-pyrimidin-2-one

A

5-bromouracil
51-20-7

5-bromouracil

B

C16H27BrN2OS
856766-63-7

C16H27BrN2OS

Conditions
ConditionsYield
With bromine In tetrachloromethane at 20℃;A 30%
B 18%
C18H32N2OS

C18H32N2OS

A

5-bromouracil
51-20-7

5-bromouracil

B

C18H31BrN2OS
856766-64-8

C18H31BrN2OS

Conditions
ConditionsYield
With bromine In tetrachloromethane at 20℃;A 30%
B 21%
4-Hexadecylsulfanyl-1H-pyrimidin-2-one

4-Hexadecylsulfanyl-1H-pyrimidin-2-one

A

5-bromouracil
51-20-7

5-bromouracil

B

C20H35BrN2OS
856766-65-9

C20H35BrN2OS

Conditions
ConditionsYield
With bromine In tetrachloromethane at 20℃;A 30%
B 22%
4-Octadecylsulfanyl-1H-pyrimidin-2-one

4-Octadecylsulfanyl-1H-pyrimidin-2-one

A

5-bromouracil
51-20-7

5-bromouracil

B

C22H39BrN2OS

C22H39BrN2OS

Conditions
ConditionsYield
With bromine In tetrachloromethane at 20℃;A 30%
B 20%
5,5-dibromo-6-hydroxy-5,6-dihydrouracil
1124-83-0

5,5-dibromo-6-hydroxy-5,6-dihydrouracil

A

5-bromouracil
51-20-7

5-bromouracil

B

[5,5']bipyrimidinyl-2,4,6,2',4',6'-hexaone
476-61-9

[5,5']bipyrimidinyl-2,4,6,2',4',6'-hexaone

Conditions
ConditionsYield
With water
1-acetyl-5-bromo-1H-pyrimidine-2,4-dione

1-acetyl-5-bromo-1H-pyrimidine-2,4-dione

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With hydrogenchloride
5-bromo-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
15018-62-9

5-bromo-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid

5-bromouracil
51-20-7

5-bromouracil

Cytosine
71-30-7

Cytosine

A

5-bromouracil
51-20-7

5-bromouracil

B

5-bromocytosine
2240-25-7

5-bromocytosine

Conditions
ConditionsYield
With bromine In tetrachloromethane; water at 25℃; for 1h; Title compound not separated from byproducts;A 17 % Spectr.
B 73 % Spectr.
5-Bromo-6-hydroxyamino-dihydro-pyrimidine-2,4-dione

5-Bromo-6-hydroxyamino-dihydro-pyrimidine-2,4-dione

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With hydroxylamine at 25℃; Equilibrium constant; var. pH;
hydrogenchloride
7647-01-0

hydrogenchloride

5,5-dibromo-6-hydroxy-5,6-dihydrouracil
1124-83-0

5,5-dibromo-6-hydroxy-5,6-dihydrouracil

water
7732-18-5

water

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
at 25℃; Rate constant;
5-bromo-2-ethylsulfanyl-pyrimidone-(4)

5-bromo-2-ethylsulfanyl-pyrimidone-(4)

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With hydrogenchloride
5-bromo-2-methoxy-1H-pyrimidin-4-one

5-bromo-2-methoxy-1H-pyrimidin-4-one

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
With hydrogenchloride
cytidine nitrate

cytidine nitrate

A

5-bromouracil
51-20-7

5-bromouracil

B

D-ribonic acid
642-98-8

D-ribonic acid

Conditions
ConditionsYield
With hydrogen bromide; bromine
uracil
66-22-8

uracil

water

water

bromine

bromine

5-bromouracil
51-20-7

5-bromouracil

Conditions
ConditionsYield
Mechanism;
2,4-dichloro-5-bromopyrimidine
36082-50-5

2,4-dichloro-5-bromopyrimidine

antimony(III) fluoride
7783-56-4

antimony(III) fluoride

A

5-fluorouracil
51-21-8

5-fluorouracil

B

5-bromouracil
51-20-7

5-bromouracil

2,4-dichloro-5-bromopyrimidine
36082-50-5

2,4-dichloro-5-bromopyrimidine

A

5-bromouracil
51-20-7

5-bromouracil

B

uracil
66-22-8

uracil

tetrabromo aurate (III) (1-)
14337-14-5

tetrabromo aurate (III) (1-)

uracil
66-22-8

uracil

A

5-bromouracil
51-20-7

5-bromouracil

B

dibromidoaurate(I)

dibromidoaurate(I)

Conditions
ConditionsYield
In dimethylsulfoxide-d6; water Kinetics; byproducts: 5-bromo-6-hydroxy-5,6-dihydrouracil; reduction reaction at 25°C; monitored by NMR-spectroscopy;
In dimethylsulfoxide-d6 Kinetics; reduction reaction at 25°C; monitored by (1)H-NMR-spectroscopy;
5-bromouridine
957-75-5

5-bromouridine

A

5-bromouracil
51-20-7

5-bromouracil

B

C5H9O8P(2-)*2K(1+)

C5H9O8P(2-)*2K(1+)

Conditions
ConditionsYield
With potassium dihydrogenphosphate; E-pyrimidine nucleoside phosphorylase-0002 In aq. buffer at 40℃; for 0.666667h; pH=9; Equilibrium constant; Thermodynamic data; Temperature; Enzymatic reaction;
5-bromo-2'-deoxyuridine
59-14-3

5-bromo-2'-deoxyuridine

A

5-bromouracil
51-20-7

5-bromouracil

B

C5H9O7P(2-)*2K(1+)

C5H9O7P(2-)*2K(1+)

Conditions
ConditionsYield
With potassium dihydrogenphosphate; E-pyrimidine nucleoside phosphorylase-0002 In aq. buffer at 40℃; for 0.666667h; pH=9; Equilibrium constant; Thermodynamic data; Temperature; Enzymatic reaction;
1-methyl-piperazine
109-01-3

1-methyl-piperazine

5-bromouracil
51-20-7

5-bromouracil

5-(4-methylpiperazin-1-yl) pyrimidine-2,4(1H,3H)-dione
141692-30-0

5-(4-methylpiperazin-1-yl) pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With pyridine at 150℃; for 0.75h; Microwave irradiation;100%
In neat (no solvent) at 120℃; Microwave irradiation;91%
for 0.25h; Heating;65%
5-bromouracil
51-20-7

5-bromouracil

C4H4BrN2O2
78907-31-0

C4H4BrN2O2

Conditions
ConditionsYield
With H2SO4 glasses Product distribution; Irradiation;100%
5-bromouracil
51-20-7

5-bromouracil

2,4-dichloro-5-bromopyrimidine
36082-50-5

2,4-dichloro-5-bromopyrimidine

Conditions
ConditionsYield
With phosphorus pentachloride In 1,1,2-trichloroethane Reagent/catalyst; Solvent; Reflux;99.5%
With N,N-dimethyl-aniline; trichlorophosphate at 120 - 130℃; for 1.33333h;96.6%
With phosgene; Tributylphosphine oxide at -5 - 125℃; for 1.83333h; Inert atmosphere;89.7%
chloro-trimethyl-silane
75-77-4

chloro-trimethyl-silane

5-bromouracil
51-20-7

5-bromouracil

2,4-bis-(trimethylsilyloxy)-5-bromopyrimidine
33282-64-3

2,4-bis-(trimethylsilyloxy)-5-bromopyrimidine

Conditions
ConditionsYield
With 1,1,1,3,3,3-hexamethyl-disilazane Ambient temperature;99%
With 1,1,1,3,3,3-hexamethyl-disilazane at 140 - 150℃; for 5h;
With 1,1,1,3,3,3-hexamethyl-disilazane
With ammonium sulfate; 1,1,1,3,3,3-hexamethyl-disilazane for 18h; Heating;
5-bromouracil
51-20-7

5-bromouracil

ethyl acrylate
140-88-5

ethyl acrylate

3-(5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)propionic acid ethyl ester

3-(5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)propionic acid ethyl ester

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 60℃; Aza-Micheal reaction;99%
With tetrabutylammomium bromide; zinc(II) oxide at 100℃; for 0.416667h; Michael addition; microwave irradiation;90%
With tetrabutylammomium bromide at 100℃; for 0.416667h; Microwave irradiation; Neat (no solvent);84%
With Bacillus subtilis alkaline protease EC 3.4.21.14 In dimethyl sulfoxide at 50℃; for 24h; Michael addition;68.5%
5-bromouracil
51-20-7

5-bromouracil

cyclohexylamine
108-91-8

cyclohexylamine

5-(N-cyclohexylamino)uracil
5177-53-7

5-(N-cyclohexylamino)uracil

Conditions
ConditionsYield
at 110℃; for 0.116667h; microwave irradiation;98%
5-bromouracil
51-20-7

5-bromouracil

acrylic acid methyl ester
292638-85-8

acrylic acid methyl ester

3-(3,4-dihydro-5-bromo-2,4-dioxo-(2H)pyrimidin-1-yl)propanoic acid methyl ester
22384-59-4

3-(3,4-dihydro-5-bromo-2,4-dioxo-(2H)pyrimidin-1-yl)propanoic acid methyl ester

Conditions
ConditionsYield
Stage #1: 5-bromouracil With triethylamine In N,N-dimethyl-formamide for 0.0833333h; Michael-type addition;
Stage #2: acrylic acid methyl ester In N,N-dimethyl-formamide at 20℃; for 24h; Michael-type addition; regioselective reaction;
98%
With triethylamine In N,N-dimethyl-formamide at 60℃; Aza-Micheal reaction;97%
With acylase Amano from Aspergillus oryzae In dimethyl sulfoxide at 50℃; for 3h; Michael addition reaction;91 % Chromat.
With triethylamine In N,N-dimethyl-formamide at 20℃; for 24h; Michael condensation;
5-bromouracil
51-20-7

5-bromouracil

acrylic acid n-butyl ester
141-32-2

acrylic acid n-butyl ester

3-(5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)propionic acid butyl ester
1370413-76-5

3-(5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)propionic acid butyl ester

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 60℃; Aza-Micheal reaction;98%
5-bromouracil
51-20-7

5-bromouracil

benzyl-methyl-amine
103-67-3

benzyl-methyl-amine

5-[benzyl(methyl)amino]-1H-pyrimidine-2,4-dione
141692-27-5

5-[benzyl(methyl)amino]-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 120℃; for 0.0833333h; microwave irradiation;97%
In neat (no solvent) at 120℃; for 1h; Microwave irradiation;86%
at 120℃; for 1h; Microwave irradiation;86%
at 120℃; for 1h; Microwave irradiation;86%
for 0.25h; Heating;
5-bromouracil
51-20-7

5-bromouracil

parabanic acid
120-89-8

parabanic acid

Conditions
ConditionsYield
With oxygen; ozone In acetic acid at 20℃; for 0.75h; Product distribution;97%
morpholine
110-91-8

morpholine

5-bromouracil
51-20-7

5-bromouracil

5-morpholinopyrimidine-2,4(1H,3H)-dione
37454-52-7

5-morpholinopyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 90℃; for 0.0833333h; microwave irradiation;96%
at 130℃; for 0.25h;96%
at 100℃; for 0.166667h; Microwave irradiation;89%
In neat (no solvent) at 120℃; Microwave irradiation;78%
5-bromouracil
51-20-7

5-bromouracil

N-butylamine
109-73-9

N-butylamine

5-butylaminouracil

5-butylaminouracil

Conditions
ConditionsYield
at 90℃; for 0.166667h; microwave irradiation;96%
5-bromouracil
51-20-7

5-bromouracil

ethanolamine
141-43-5

ethanolamine

5-(2'-hydroxyethylamino)uracil
55476-33-0

5-(2'-hydroxyethylamino)uracil

Conditions
ConditionsYield
In ethanol for 24h; Reflux;96%
5-bromouracil
51-20-7

5-bromouracil

5-Bromo-4-thioxo-3,4-dihydro-1H-pyrimidin-2-one
72812-45-4

5-Bromo-4-thioxo-3,4-dihydro-1H-pyrimidin-2-one

Conditions
ConditionsYield
With diphosphorus pentasulfide; sodium hydrogencarbonate In diethylene glycol dimethyl ether at 110℃; for 2h;95%
5-bromouracil
51-20-7

5-bromouracil

benzylamine
100-46-9

benzylamine

5-(benzylamino)dihydropyrimidine-2,4(1H,3H)-dione
28485-19-0

5-(benzylamino)dihydropyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 110℃; for 0.2h; microwave irradiation;95%
at 160℃; for 2h;90%
for 0.666667h; Inert atmosphere; Heating; neat (no solvent);84%
Heating; Yield given;
at 160℃; for 3h;
piperidine
110-89-4

piperidine

5-bromouracil
51-20-7

5-bromouracil

5-(N-piperidino)uracil
37454-53-8

5-(N-piperidino)uracil

Conditions
ConditionsYield
at 90℃; for 0.15h; microwave irradiation;95%
5-bromouracil
51-20-7

5-bromouracil

vinyl acrylate
2177-18-6

vinyl acrylate

3-(5-bromouracil-1-yl)propionic acid vinyl ester
1217794-07-4

3-(5-bromouracil-1-yl)propionic acid vinyl ester

Conditions
ConditionsYield
With D-aminoacylase from Escherichia coli In dimethyl sulfoxide at 25℃; for 0.416667h; Michael addition; Enzymatic reaction; regioselective reaction;95%
5-bromouracil
51-20-7

5-bromouracil

ethyl bromoacetate
105-36-2

ethyl bromoacetate

5-bromo-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidineacetic acid ethyl ester
381710-01-6

5-bromo-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidineacetic acid ethyl ester

Conditions
ConditionsYield
Stage #1: 5-bromouracil With 1,1,1,3,3,3-hexamethyl-disilazane Heating;
Stage #2: ethyl bromoacetate In acetonitrile Heating; Further stages.;
94%
With ammonium sulfate; 1,1,1,3,3,3-hexamethyl-disilazane; potassium iodide In acetonitrile at 120℃; for 1h; Time; Hilbert-Johnson Synthesis; Microwave irradiation; Autoclave; regioselective reaction;62%
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 2h;55%
With potassium carbonate In N,N-dimethyl-formamide at 20℃;
1,2,3,5-tetra-O-acetyl-3-C-ethynyl-D-ribo-pentofuranose
848644-37-1

1,2,3,5-tetra-O-acetyl-3-C-ethynyl-D-ribo-pentofuranose

5-bromouracil
51-20-7

5-bromouracil

1-[2,3,5-tri-O-acetyl-3-C-ethynyl-β-D-ribo-pentofuranosyl]-5-bromouracil
848644-42-8

1-[2,3,5-tri-O-acetyl-3-C-ethynyl-β-D-ribo-pentofuranosyl]-5-bromouracil

Conditions
ConditionsYield
With N,O-bis-(trimethylsilyl)-acetamide; trimethylsilyl trifluoromethanesulfonate In acetonitrile at 50℃; for 23h;94%
5-bromouracil
51-20-7

5-bromouracil

2-fluorobenzylamine
89-99-6

2-fluorobenzylamine

5-[(2-fluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione
867151-45-9

5-[(2-fluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 160℃; for 2h;94%
5-bromouracil
51-20-7

5-bromouracil

uracil
66-22-8

uracil

Conditions
ConditionsYield
With N,N-dimethyl acetamide at 180℃; for 7h;93.8%
With isopropyl alcohol Product distribution; Mechanism; Quantum yield; Irradiation; deuterated 2-propanol solvents;
In ethanol Product distribution; Quantum yield; Mechanism; Irradiation; further solvent;
5-bromouracil
51-20-7

5-bromouracil

2,4-Difluoro-benzylamine
72235-52-0

2,4-Difluoro-benzylamine

5-[(2,4-difluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione
867151-48-2

5-[(2,4-difluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 160℃; for 6h;93%
at 160℃; for 2h;91%
5-bromouracil
51-20-7

5-bromouracil

2-chloromethyl-1,3,5-trimethylbenzene
1585-16-6

2-chloromethyl-1,3,5-trimethylbenzene

5-bromo-1-(mesitylmethyl)pyrimidine-2,4(1H,3H)-dione
1056025-50-3

5-bromo-1-(mesitylmethyl)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
Stage #1: 5-bromouracil With benzenesulfonamide In acetonitrile for 0.25h;
Stage #2: 2-chloromethyl-1,3,5-trimethylbenzene In acetonitrile for 20h; Heating; Further stages.;
93%
5-bromouracil
51-20-7

5-bromouracil

aniline
62-53-3

aniline

5-(phenylamino)uracil
4870-31-9

5-(phenylamino)uracil

Conditions
ConditionsYield
at 180℃; for 0.25h; microwave irradiation;92%
at 195 - 200℃; for 1h;77%
In ethylene glycol Reflux;68%
With hydroquinone In ethylene glycol at 200℃; for 2h; Heating / reflux;55%
5-bromouracil
51-20-7

5-bromouracil

para-fluorobenzylamine
140-75-0

para-fluorobenzylamine

5-[(4-fluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione
867151-47-1

5-[(4-fluorobenzyl)amino]dihydropyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 160℃; for 2h;92%
5-bromouracil
51-20-7

5-bromouracil

1-chloro-2,4-dinitro-benzene
97-00-7

1-chloro-2,4-dinitro-benzene

1-(2,4-dinitro-phenyl)-5-bromo-1H-pyrimidine-2,4-dione

1-(2,4-dinitro-phenyl)-5-bromo-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
With zinc(II) oxide at 130℃; for 0.5h; Ionic liquid;92%
5-bromouracil
51-20-7

5-bromouracil

phenethylamine
64-04-0

phenethylamine

5-[(2-phenylethyl)amino]dihydropyrimidine-2,4(1H,3H)-dione
25912-34-9

5-[(2-phenylethyl)amino]dihydropyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 160℃; for 2h;91%
5-bromouracil
51-20-7

5-bromouracil

2-methoxyethylamine
109-85-3

2-methoxyethylamine

5-(2-methoxyethylamino)pyrimidine-2,4(1H,3H)-dione

5-(2-methoxyethylamino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In ethanol at 100℃; for 16h;90.4%
With potassium carbonate In tetrahydrofuran
5-bromouracil
51-20-7

5-bromouracil

ethyl 6-O-(tert-butyldimethylsilyl)-4-O-methoxycarbonyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranoside
187990-50-7

ethyl 6-O-(tert-butyldimethylsilyl)-4-O-methoxycarbonyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranoside

C18H29BrN2O5Si

C18H29BrN2O5Si

Conditions
ConditionsYield
With 1,4-di(diphenylphosphino)-butane; tetrakis(triphenylphosphine) palladium(0) In tetrahydrofuran at 50℃; for 2h;90%

51-20-7Relevant articles and documents

Ettorre, Renato,Gonzalez Sanchez, Angeles

, p. 221 - 226 (1990)

Carbonic anhydrase inhibitory properties of some uracil derivatives

Alper Türko?lu, Emir,?entürk, Murat,Supuran, Claudiu T.,Ekinci, Deniz

, p. 74 - 77 (2017)

Inhibitors of carbonic anhydrase (CA) have been carried out in many therapeutic applications, especially antiglaucoma activity. In this study, we investigated some uracil derivatives (4–12) to inhibit human CA I (hCA I) and II (hCA II) isoenzymes. The KI values of the compounds 4–12 are in the range of 0.085–428 μM for hCA I and of 0.1715–645 μM against hCA II, respectively. It is concluded from the kinetic investigations, all compounds used in the study act as competitive inhibitors with substrate, 4-NPA. Uracil derivatives are emerging agents for the inhibiton of carbonic anhydrase which could be used in biomedicine.

-

Riederer et al.

, p. 313 (1978)

-

Thermodynamic Reaction Control of Nucleoside Phosphorolysis

Kaspar, Felix,Giessmann, Robert T.,Neubauer, Peter,Wagner, Anke,Gimpel, Matthias

supporting information, p. 867 - 876 (2020/01/24)

Nucleoside analogs represent a class of important drugs for cancer and antiviral treatments. Nucleoside phosphorylases (NPases) catalyze the phosphorolysis of nucleosides and are widely employed for the synthesis of pentose-1-phosphates and nucleoside analogs, which are difficult to access via conventional synthetic methods. However, for the vast majority of nucleosides, it has been observed that either no or incomplete conversion of the starting materials is achieved in NPase-catalyzed reactions. For some substrates, it has been shown that these reactions are reversible equilibrium reactions that adhere to the law of mass action. In this contribution, we broadly demonstrate that nucleoside phosphorolysis is a thermodynamically controlled endothermic reaction that proceeds to a reaction equilibrium dictated by the substrate-specific equilibrium constant of phosphorolysis, irrespective of the type or amount of NPase used, as shown by several examples. Furthermore, we explored the temperature-dependency of nucleoside phosphorolysis equilibrium states and provide the apparent transformed reaction enthalpy and apparent transformed reaction entropy for 24 nucleosides, confirming that these conversions are thermodynamically controlled endothermic reactions. This data allows calculation of the Gibbs free energy and, consequently, the equilibrium constant of phosphorolysis at any given reaction temperature. Overall, our investigations revealed that pyrimidine nucleosides are generally more susceptible to phosphorolysis than purine nucleosides. The data disclosed in this work allow the accurate prediction of phosphorolysis or transglycosylation yields for a range of pyrimidine and purine nucleosides and thus serve to empower further research in the field of nucleoside biocatalysis. (Figure presented.).

A 5 - bromo uracil preparation method

-

Paragraph 0033-0040, (2019/10/04)

The invention discloses a preparation method for 5-bromouracil. By taking uracil as an initial raw material, sodium bromide and sodium hypochlorite as a green bromating agent, and water as a solvent, a mild brominating reaction is carried out under an acidic condition to obtain a high purity target product. The preparation method disclosed by the invention is green and environmental-friendly in synthetic process, convenient in post-treatment and suitable for large-scaled industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51-20-7